Journal Article

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Lapointe, Rejean, Al, Kait F., Maleki Vareki, Saman, Lenehan, John G., Jamal, Rahima, Belanger, Karl, Silverman, Michael S., Miller, Wilson H., Logan, Diane, Krishnamoorthy, Mithunah, Ernst, Scott, Esfahani, Khashayar, Segata, Nicola, Ramsay, LeeAnn, Watson, Ian R., Messaoudene, Meriem, Parvathy, Seema Nair, Martinez-Gili, Laura, Armanini, Federica, Ninkov, Marina, Derosa, Lisa, Magrill, Jamie, Hes, Cecilia, Takis, Panteleimon, Pinto, Federica, Figueredo, Rene, Routy, Bertrand, Mullish, Benjamin H., Elkrief, Arielle, Haeryfar, S.M. Mansour, Marchesi, Julian R., Punčochář, Michal, Daisley, Brendan A., Richard, Corentin, Piccinno, Gianmarco, Thebault, Pamela, Burton, Jeremy P.

2023

Overview

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining healthy donor FMT with the PD-1 inhibitors nivolumab or pembrolizumab in 20 previously untreated patients with advanced melanoma. The primary end point was safety. No grade 3 adverse events were reported from FMT alone. Five patients (25%) experienced grade 3 immune-related adverse events from combination therapy. Key secondary end points were objective response rate, changes in gut microbiome composition and systemic immune and metabolomics analyses. The objective response rate was 65% (13 of 20), including four (20%) complete responses. Longitudinal microbiome profiling revealed that all patients engrafted strains from their respective donors; however, the acquired similarity between donor and patient microbiomes only increased over time in responders. Responders experienced an enrichment of immunogenic and a loss of deleterious bacteria following FMT. Avatar mouse models confirmed the role of healthy donor feces in increasing anti-PD-1 efficacy. Our results show that FMT from healthy donors is safe in the first-line setting and warrants further investigation in combination with immune checkpoint inhibitors. ClinicalTrials.gov identifier NCT03772899 . In patients with advanced melanoma, fecal microbiota transplantation from healthy donors combined with the anti-PD-1 inhibitors nivolumab or pembrolizumab was well tolerated with an encouraging objective response rate of 65% in the first-line treatment setting.

• Publisher: Nature Publishing Group US,Nature Publishing Group
• Subject: 631/250/251 / 631/326/2565/2134 / 631/67/1813/1634 / Adverse events / Animal models / Animals / Biomedical and Life Sciences / Biomedicine / Cancer Research / Donors / Fecal Microbiota Transplantation - methods / Fecal microflora / Feces / Feces - microbiology / Immune Checkpoint Inhibitors / Immune response / Immunogenicity / Immunotherapy / Infectious Diseases / Inhibitors / Intestinal microflora / Melanoma / Melanoma - therapy / Metabolic Diseases / Metabolomics / Mice / Microbiomes / Microbiota / Microorganisms / Molecular Medicine / Monoclonal antibodies / Neurosciences / PD-1 protein / Pembrolizumab / Response rates / Transplantation / Treatment Outcome